Search results for "Predictive factor"

showing 10 items of 30 documents

Does pain intensity predict a poor opioid response in cancer patients?

2011

Abstract Aim The aim of this study was to test the hypothesis that initial pain intensity is not a predictive factor of poor opioid response in advanced cancer patients, as suggested by a recent work. Methods A secondary analysis of one-hundred-sixty-seven patients referred for treatment of cancer-related pain was conducted. Pain intensity at admission was recorded and patients were divided in three categories of pain intensity: mild, moderate and severe. Patients were offered a treatment with opioid dose titration, according to department policy. Data regarding opioid doses and pain intensity were collected after dose titration was completed. Four levels of opioid response were considered:…

MaleCancer ResearchOpioid responseopioid response in cancer patientPainOpioidSettore MED/42 - Igiene Generale E ApplicataSecondary analysisNeoplasmsmedicineHumansProspective StudiesCancer painKarnofsky Performance StatusAdverse effectAgedPain Measurementpain intensityAnalgesicsAnalysis of VarianceAssessment tools; Cancer pain; Opioid response; Aged; Analgesics Opioid; Analysis of Variance; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Prospective Studies; Treatment Outcome; Cancer Research; Oncologybusiness.industryCancerMiddle Agedmedicine.diseaseAdvanced cancerIntensity (physics)Predictive factorAnalgesics OpioidAssessment toolsTreatment OutcomeOncologyOpioidAnesthesiapain intensity; opioid response in cancer patients; trial clinicoFemaletrial clinicoCancer painbusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Correlation between classical prognostic factors and overexpression of HER2 and HER3 in localized gastric cancer

2012

e14589 Background: Although HER2 overexpression has been identified as a predictive factor for targeted therapy in advanced gastric cancer (GC), little is known about its role in localized GC. Recent studies suggest that not only HER2 but also HER3 might have a role in prognosis in GC. Our study aimed to identify the prevalence of HER2 and HER3 overexpression in a series of localized GC and to describe correlations of these with traditional prognostic factors Methods: We performed a retrospective analysis of HER2 and HER3 overexpression in archived tumour samples in pts diagnosed with GC at stage I-III. HER2 was assessed with herceptest, (negative if 0 or 1+, or positive with 2+ or 3+). St…

OncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancermedicine.diseaseHercepTestPredictive factorTargeted therapybody regionsCorrelationOncologyInternal medicinemedicineStatistical analysisStage (cooking)skin and connective tissue diseasesReceptorbusiness
researchProduct

Stress Hyperglycemia as Predictive Factor of Recurrence in Children with Febrile Seizures

2020

Stress hyperglycemia and hyperlactatemia are commonly referred to as markers of stress severity and poor outcome in children with severe acute illness or febrile seizures. Our prospective study aimed to explore the risk factors for stress hyperglycemia and the predictive value of stress hyperglycemia for febrile seizure recurrence. We evaluated as risk factors for blood glucose level, serum lactate, acid&ndash

medicine.medical_specialtyrecurrenceendocrine system diseasesContext (language use)030204 cardiovascular system & hematologyStress hyperglycemiaGastroenterologyhyperlactatemiaArticlelcsh:RC321-57103 medical and health sciences0302 clinical medicineInterquartile rangeFebrile seizureInternal medicinemedicineAcute stress reactionProspective cohort studylcsh:Neurosciences. Biological psychiatry. Neuropsychiatrystress hyperglycemiabusiness.industryGeneral Neurosciencenutritional and metabolic diseasesmedicine.diseasemetabolic statusPredictive factorHyperlactatemiafebrile seizurebusiness030217 neurology & neurosurgeryBrain Sciences
researchProduct

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

2023

BackgroundMerkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outcomes in obese patients following treatment with ICIs, known as the “obesity paradox”, has been studied across many types of tumors. Probably due to the rarity of this tumor, data on mMMC patients are lacking.Patients and methodsThis is an observational, hospital-based, study to investigate the role of Body Mass Index (BMI) as predictive biomarker of ICI response in mMCC patients treated with aveluma…

Cancer Researchpredictive factorsOncologyskin cancer non melanomaavelumabimmunotherapybody mass index - BMIMerkel cell carcinoma (MCC)Frontiers in Oncology
researchProduct

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer

2016

International audience; Background: To determine whether dose/volume specific endpoints (DVSE) or Area under the rectal DVH curve (rAUC) better predict acute gastrointestinal (GI) toxicity in prostate cancer patients treated with IMRT in the era of daily image guidance (IG-IMRT). Methods: A set of DVSE was recorded from V25 to V75 (increments of 5Gy) (both in % and in cc) for 180 men. The rAUC was calculated for doses ranging between 25Gy and 50Gy (rAUC(25-50)). Univariate and multivariate logistic regressions were performed to determine the relationship between DVSE or rAUC(25-50) and the appearance of any acute GI toxicity. Results: The rates of acute grade 1 (G1), G2 and G3 GI toxicities…

OncologyMale[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterology030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineProstate cancer0302 clinical medicineProstateLarge intestineConformal Radiation-Therapy[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overGastrointestinal tractProstate cancerRadiotherapy DosageMiddle Aged3. Good healthmedicine.anatomical_structureImpactOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisArea Under CurveToxicityImage Guidancemedicine.medical_specialtyRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesInternal medicinemedicineBiochemical ControlHumansRadiology Nuclear Medicine and imagingRadiation InjuriesAgedRadiotherapybusiness.industryResearchRectumProstatic Neoplasmsmedicine.diseaseRadiation therapyAcute rectal toxicity predictive factorLogistic ModelsRadiotherapy Intensity-ModulatedbusinessAbsolute volumeRadiation Oncology (London, England)
researchProduct

Does age over 80 years have to be a contraindication for lung cancer surgery—a nationwide database study

2018

IF 1.804 (2017); International audience; Background: Nowadays surgery remains the best treatment for localized lung cancer (LC). However, patients over 80 years old are often denied surgery because of the postoperative risk of death. This study aimed to estimate in-hospital mortality (IHM) and determine whether age over 80 is the most important predictor of IHM after LC surgery.Methods: From January 2005 to December 2015, 97,440 patients, including 4,438 patients over 80 years old, were operated on for LC and recorded in the French Administrative Database. Characteristics of patients, hospitals and surgery were analysed.Results: Crude IHM was 3.73% (n=3,639) and 7.77% (n=345) for the over 8…

Pulmonary and Respiratory Medicinemedicine.medical_specialtylobectomypredictive factors[SDV.CAN]Life Sciences [q-bio]/Cancer030230 surgery03 medical and health sciencesLiver disease0302 clinical medicinePostoperative riskmedicineLung cancerContraindicationLung cancer surgerybusiness.industryOver 80sNationwide databasein-hospital mortality (IHM)medicine.diseaseSublobar resection3. Good healthSurgeryOriginal ArticlePulmonary resectionbusinessnationwide database
researchProduct

Predictive Factors of Abdominal Compartment Syndrome in Neonatal Age

2014

In the pediatric population, abdominal compartment syndrome (ACS) is a known complication of abdominal wall defect repair. However, there are only few reports on ACS in newborns and only a proposal of critical intra-abdominal pressure value (IAP) in term newborns, absent in preterm newborns. Although the prevalent clinical sign is tense abdominal distension, it may be difficult to distinguish ACS from pathologies that will not require decompression. The purpose of this study was to identify predictors for ACS and therefore morbidity or mortality indicators. We reviewed newborns presenting with tense abdominal distension and end organ failure. Anamnestic, clinical, laboratory, and instrument…

MalePediatricsmedicine.medical_specialtyNeonatal intensive care unitAbdominal compartment syndromePopulationGestational AgeAbdominal wallSettore MED/38 - Pediatria Generale E SpecialisticaIntubation IntratrachealHumansMedicineLactic AcideducationAbdominal Compartment Syndrome Predictive Factors in Neonatal AgeRetrospective Studieseducation.field_of_studybusiness.industryIncidenceAbdominal wall defectAbdominal WallInfant NewbornObstetrics and GynecologyGestational ageAbdominal distensionmedicine.diseaseRespiration ArtificialSurgerymedicine.anatomical_structureCase-Control StudiesPediatrics Perinatology and Child HealthApgar ScoreFemaleIntra-Abdominal HypertensionIntra-Abdominal Hypertensionmedicine.symptombusinessAmerican Journal of Perinatology
researchProduct

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…

2012

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…

Malerheumatoid arthritisArthritisReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidAdalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis FactorsRheumatoidadalimumabMonoclonalReceptorsImmunology and AllergyRegistriesinfectionsHumanizedAnti-TNF agents; GISEA register; Infections; Predictive factorsIncidence (epidemiology)IncidenceAntibodies MonoclonalAnti-TNF agentsMiddle AgedRheumatoid arthritisAntirheumatic AgentsCohortTumor Necrosis FactorsFemaleInfectionPredictive factorsmedicine.druganti-TNF; serious infections; rheumatoid arthritisAdultmedicine.medical_specialtyanti-TNF therapy; infections; rheumatoid arthritis; adalimumab; etanercept; infliximabanti-TNF therapyserious infectionsImmunologyInfections rheumatoid arthritis anti-TNF therapyAntibodies Monoclonal HumanizedInfectionsAntibodiesInternal medicinemedicineAdalimumabHumansAgedGISEA registerbusiness.industryArthritisAdalimumabanti-TNFGISEA register; Infections; Anti-TNF agents; Predictive factors; Adalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis Factorsmedicine.diseaseInfliximabInfliximabConcomitantImmunoglobulin GImmunologyTumor Necrosis Factor InhibitorsbusinessTumor Necrosis Factorinfliximabetanercept
researchProduct

Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

2021

Background and Aim: Lenvatinib is a standard of care option in first-line therapy of advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in patients with HCC treated with lenvatinib, a possible association between occurrence and grading of adverse events (AEs) and outcome. Methods: We performed a retrospective analysis of 606 Japanese and Italian patients treated with lenvatinib in first-line setting and investigated the possible correlation between the onset of AEs, toxicity grade (G) and outcome measures such as overall survival (OS) and progression-free survival (PFS). Results: The appearance of arterial hypertension G ≥ 2 independently predicted prolonged …

Phenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularMultivariate analysispredictive factorsadverse eventlenvatinibGastroenterologypredictive factorchemistry.chemical_compoundQuality of lifeInternal medicinemedicineHumansAdverse effectRetrospective Studiesadverse events; hepatocellular carcinoma; lenvatinib; predictive factorsSettore MED/12 - GastroenterologiaHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsHazard ratiohepatocellular carcinomamedicine.diseaseadverse eventsConfidence intervalDiscontinuationchemistryLiver NeoplasmHepatocellular carcinomaQuality of LifeQuinolinesLenvatinibbusiness
researchProduct